Scientific ReportsBiochemistryPeer-reviewed journal article
Discovery of first-in-class inhibitors of the TRF1-TIN2 protein-protein interaction by fragment screening
Giacomo Casale, Manjuan LiuiD, Yann‐Vaï Le BihaniD, Oviya InianiD, Ellie Stammers, John CaldwelliD, Rob L. M. van MontfortiD, Ian CollinsiD, Sebastian GuettleriD
Abstract
TRF1 is a subunit of the shelterin complex that binds to and protects the linear ends of chromosomes known as telomeres. Both genetic deletion and chemical inhibition of TRF1 have been shown to block the growth of lung carcinoma, glioblastoma, and renal cell carcinoma in mice without affecting mouse survival or tissue function, making TRF1 a potential therapeutic target in cancer1-3. Here, we report the discovery of a series of fragment hits that bind at the interface between the TRFH domain of TRF1 (TRF1TRFH) and a peptide of TIN2 (TIN2TBM), an interaction essential for the recruitment of TRF1 to shelterin, using X-ray crystallography (XChem) and ligand-observed NMR (LO-NMR) fragment screening. We discovered a first-in-class inhibitor of the TRF1-TIN2 interaction (compound 40) that binds to TRF1TRFH with a KD of 29 M (95% CI: 20 - 41 M), displaces a TIN2 probe with an IC50 of 67 {+/-} 28 M, and expels TRF1 from purified shelterin. Aided by a novel crystal system of TRF1TRFH, we characterised fragments binding in a hotspot at the TRF1-TIN2 interface which will serve as a starting point for the structure-guided development of potent inhibitors of TRF1 protein-protein interactions to disrupt shelterin complex assembly.
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 33th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural Characterization of TRAF6 N-terminal for Therapeutic Uses
Ömür Güven, Halil I. Ciftci, … Hasan DeMi̇rci̇·bioRxiv·Feb 25, 2023
- The Discovery of Small Molecule Inhibitors of cFLIP that Sensitise Tumour Cells to TRAIL
Gilda Giancotti, Rhiannon French, … Andrea Brancale·Academia oncology.Peer-reviewed·Apr 29, 2025
- Development of PROTACs for targeted degradation of oncogenic TRK fusions
Saurav Kumar, Jiewei Jiang, … Behnam Nabet·RSC Chemical BiologyPeer-reviewed·Jan 1, 2026
- Temperature-Related Intensity Change (TRIC)-based High Throughput Screening Platform for the Discovery of CHI3L1-Targeted Small Molecules
Longfei Zhang, Moustafa Tarek Gabr·SLAS DISCOVERYPeer-reviewed·Oct 1, 2025
- Therapeutic vulnerability to ATR inhibition in concurrent NF1 and ATRX-deficient high-grade solid tumors
M. Yuan, C. G. Eberhart, … F. J. Rodriguez·bioRxiv·Feb 3, 2022
- Chemo-phosphoproteomic profiling with ATR inhibitors berzosertib and gartisertib uncovers new biomarkers and DNA damage response regulators
R. S. Jadav, F. Weiland, … J. Rouse·bioRxiv·Apr 3, 2023